CrystalGenomics Participates in 'Bio Europe 2021'

[Asia Economy Reporter Hyungsoo Park] CrystalGenomics announced on the 20th that it will participate in ‘BIO-EUROPE 2021,’ one of the world's largest bio events.

From the 25th to the 28th (local time), the company will participate in the online ‘BIO-EUROPE’ event and hold meetings with more than 30 major global bio and pharmaceutical companies such as Novartis, Daiichi Sankyo, and Menarini Pharmaceuticals. It is expected that discussions for global partnering of the pancreatic cancer drug candidate Ivaltinostat and the osteoarthritis treatment drug Aselex will continue.

Among the major pipelines, multinational bio companies are showing interest in the phase 2 clinical data of the pancreatic cancer drug candidate ‘Ivaltinostat,’ the development direction in the U.S., and the development status of additional indications such as liver cancer and COVID-19 treatments.

Celebrating its 27th year, BIO-EUROPE, the largest healthcare event in Europe, hosts over 2,600 pharmaceutical and bio industry professionals and institutional investors from 1,500 companies across 50 countries worldwide, introducing the latest bio research achievements and bio development technologies.

A CrystalGenomics official said, "BIO-EUROPE will provide an opportunity for in-depth discussions to expand networks with various bio companies."